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We greatly appreciate the valuable comments and sugges-
tions on our article1 by the reader. The reader’s main
concern regarding our manuscript was the study design. He
has rightly pointed out that perhaps the best study design to
compare clinical equivalence of the bronchodilator drugs is
that the use of at least two doses of each agent to calculate
a rudimentary dose response curve for each agent, and then
determine clinical equivalence with the help of relative
potency, and most regulatory agencies recommend this
study design. This is important because if subjects are near
the plateau of the dose response curve, the ability of the
study to discriminate differences, in bronchodilitation,
between the two treatment groups may diminish, and on
the other hand, the comparison of duration of response from
a plateau level of dose response curve may be subjected to
high variability.
However, we feel that such multiple dose studies are
more feasible when we are studying short acting broncho-
dilators, where the bronchodilator response with different
doses can be assessed on the same single day. On the other
hand, in the studies involving longer acting bronchodilators
the only acceptable study design is a single dose separate
day study. This means that two or more doses of each
tiotropium formulation, and placebo, had to be adminis-
tered each on a separate day, making a total of at least ﬁve
study visits in this study. We cannot neglect an important
point, that most of the study subjects were severe COPDs,
although stable, on oral medications (not properly treated)
and had never received a bronchodilator. Hence, there was a
risk that these subjects would have shown a variable
baseline FEV1 and FEV1 reversibility, on different study visit
days, this could have reduced the potential of discriminating
improvements (sensitivity) in lung function parameters in
some patients on certain study days.2 Therefore, we
compared a single dose of tiotropium (18mcg), which is a
long-acting anticholinergic, delivered through DPI and pMDI
plus a spacer. To our knowledge, this was the ﬁrst pMDI
formulation of tiotropium that we studied and our main
objective was to determine whether the bronchodilator
effect of pMDI formulation is at least as good as DPI
formulation.ont matter & 2007 Elsevier Ltd. All rights reserved.
2007.12.016
ticle: 10.1016/j.rmed.2007.12.015It may be very likely that that the dose of 18mcg of
tiotropium that we used in both the delivery devices, may
have produced a maximum bronchodilator response and may
therefore be on a bronchodilator plateau phase. Our results
tend to indicate that had we used a lower dose of tiotropium
(9mcg) via the pMDI formulation, we may have observed the
same bronchodilator response as that of 18mcg of tiotro-
pium via DPI formulation. It is also known that the particle
size in pMDI formulation is smaller than that administered
via DPI formulation and may therefore have better drug
deposition with consequent better therapeutic efﬁcacy. This
certainly needs to be explored and we are currently
designing a study, with two doses, to explore this.
We understand the readers concern regarding the sample
size of 19 subjects in our study, to establish equivalence and
the fact that 59% change in AUC % change in FEV1 could not
be statistically appreciated, an absolute valuable observa-
tion. Here we would like to mention, although we used the
clinical equivalence design to calculate the sample size, our
main aim was to determine whether the bronchodilator
effect of tiotropium administered via a new formulation
(pMDI) was at least as good as that administered via a
standard DPI. In this study we had essentially four primary
efﬁcacy variables. The ﬁrst one being mean maximum
difference in FEV1 and FVC from the baseline, because of
which we had used, to achieve a power of 80% and
determine equivalence at the signiﬁcance level of 5%, a
clinically signiﬁcant difference in FEV1 of 100ml and a
standard deviation in FEV1 of 150ml (based on our data of
COPD having moderate to severe COPD), to estimate the
sample size of 18 subjects. While the other primary end
points AUC % change in FEV1 and FVC were not used to
estimate the sample size, hence a difference of AUC
between the reference and test drug could not be
discriminated statistically.
The reviewer has raised a concern regarding an apparent
similarity, as observed in Figure 4, of the mean maximum
change of FEV1 between the 18mcg of tiotropium delivered
through a DPI, a pMDI plus a spacer and the placebo, which
we feel is incorrect, as the difference between the mean
maximum change in FEV1 with the tiotropium delivered
through a DPI and the placebo was 176ml and pMDI plus
spacer and the placebo was 222ml, which is higher than the
range of 7100ml to establish equivalence, while on the
other hand the difference between the mean maximum
change in FEV1 with the tiotropium delivered through a DPI
and a PMDI plus spacer was only 38ml, which is much lesser
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tiotropium through both the delivery system was equivalent.
In conclusion, we completely agree with the reviewer
that different formulations may show different receptor
occupancy in the airways and hence different bronchodi-
lator responses, which can only be studied with dose
potency studies. Now that we have this data, it would be
worthwhile to study a multiple dose responses to see for
relative potency of tiotropium in pMDI formulation.
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